Margaret A Cascieri

US Patent:

6511827, Jan 28, 2003

Filed:

Jun 16, 2000

Appl. No.:

09/595549

Inventors:

Andrew D. Howard - Park Ridge NJ
Margaret A. Cascieri - East Windsor NJ
Roy G. Smith - Houston TX
Kathleen A. Sullivan - Springfield NJ
Carina Tan - Metuchen NJ
Leonardus H. T. Van Der Ploeg - Scotch Plains NJ
Kevin R. Lynch - Charlottesville VA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C12N 1512

US Classification:

435 691, 4353201, 435325, 536 235

Abstract:

A new galanin receptor, GALR3, is described. Also provided are nucleic acids encoding same and various assays to identify ligands particular to said receptor. Ligands so identified are useful for the treatment of obesity, treatment of pain, and treatment of cognitive disorders.

US Patent:

7029868, Apr 18, 2006

Filed:

Feb 13, 2001

Appl. No.:

10/204200

Inventors:

Kathleen A. Sullivan - Springfield NJ, US
Diana Benincasa - Elizabeth NJ, US
Margaret A. Cascieri - East Windsor NJ, US
Lyndon J. Mitnaul - Piscataway NJ, US
Lin-Lin Shiao - Westfield NJ, US
Michael R. Tota - Middletown NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12Q 1/34
C12Q 1/00
C12N 5/00
C12N 15/02
C07H 19/04

US Classification:

435 18, 435 4, 435325, 435449, 435346, 536 266

Abstract:

Methods of identifying inhibitors of the fusion of two types of cells, particularly when fusion is mediated by the interaction of a viral protein and such cellular proteins as CD4 and chemokine receptors, are disclosed. The methods are suitable for identifying substances that are useful for the treatment and prevention of viral diseases. Particularly preferred methods are useful for the identification of inhibitors of HIV-1 infection.

US Patent:

20030023074, Jan 30, 2003

Filed:

Aug 6, 2002

Appl. No.:

10/212980

Inventors:

Andrew Howard - Park Ridge NJ, US
Margaret Cascieri - East Windsor NJ, US
Roy Smith - Houston TX, US
Kathleen Sullivan - Springfield NJ, US
Carina Tan - Metuchen NJ, US
Leonardus Van Der Ploeg - Scotch Plains NJ, US
Kevin Lynch - Charlottesville VA, US

Assignee:

Merck & Co., Inc.

International Classification:

C12P021/02
C12N005/06
C07K014/705
C07H021/04

US Classification:

536/023500, 530/350000, 435/069100, 435/320100, 435/325000

Abstract:

A new galanin receptor, GALR3, is described. Also provided are nucleic acids encoding same and various assays to identify ligands particular to said receptor. Ligands so identified are useful for the treatment of obesity, treatment of pain, and treatment of cognitive disorders.

US Patent:

48762423, Oct 24, 1989

Filed:

Sep 21, 1987

Appl. No.:

7/099367

Inventors:

Joy D. Applebaum - North Brunswick NJ
Marvin L. Bayne - Westfield NJ
Margaret A. Cascieri - East Windsor NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3726
C07K 710
C07K 740

US Classification:

514 3

Abstract:

A synthetic gene encoding a 71-amino acid analog of human insulin-like grouwth factor (hIGF-I) has been constructed and expressed in the yeast, Saccharomyces cerevisiae. The protein analog, IGF132, contains the first 17 amino acids of the B chain of human insulin in place of the first 16 amino acids of hIGF-I. The purified hybrid protein has high affinity for the type I IGF recepto (12 nM) yet has drastically reduced affinity for human serum carrier proteins (>1000 nM). This analog is 5 to 10 times more active than normal hIGF-I in stimulating DNA synthesis in 3T3 cells and is a more active growth factor in vivo due to its reduced affinity for serum carrier proteins. Other proteins with similar properties have also been constructed. The protein analogs thus have a variety of utilities such as in promoting lactation in animals; promoting growth and feed efficiency in animals; improving carcass quality by increasing lean and decreasing fat; promoting wound healing in animals, including humans; promoting glucose utilization in skeletal muscle, and stimulating erythropoiesis, the production of red blood cells.

US Patent:

60019700, Dec 14, 1999

Filed:

May 6, 1997

Appl. No.:

8/817869

Inventors:

Margaret A. Cascieri - East Windsor NJ
Douglas John MacNeil - Westfield NJ
Catherine D. Strader - Verona NJ

Assignee:

Merck & Co., Inc - Rayway NJ

International Classification:

C07K 14705
C07H 2104
C12P 1511

US Classification:

530350

Abstract:

Modified neuropeptide Y receptors having deletions, replacements or additions in the third intracellular domain are identified and methods of making the modified receptors are provided. The invention includes the modified receptors, assays employing the modified receptors, cells expressing the modified receptors, compounds identified through the use of the modified receptors, including modulators of the receptors, and the use of the compounds to treat conditions, including obesity, diabetes, anxiety, hypertension, cocaine withdrawal, congestive heart failure, memory enhancement, cardiac and cerebral vasospasm, pheochromocytoma and ganglioneuroblastoma, and Huntington's, Alzheimer's and Parkinson's diseases.

US Patent:

59392630, Aug 17, 1999

Filed:

Jul 25, 1997

Appl. No.:

8/894236

Inventors:

Margaret A. Cascieri - East Windsor NJ
Douglas J. MacNeil - Westfield NJ
Lin-Lin Shiao - Avenel NJ
David H. Weinberg - Westfield NJ
Carina P. Tan - Metuchen NJ
David L. Linemeyer - Westfield NJ
Catherine D. Strader - Verona NJ

Assignee:

Merck & Co., Ltd. - Rahway NJ

International Classification:

C12Q 168
C12Q 102
C12N 1585
C12N 510

US Classification:

435 6

Abstract:

A novel mammalian neuropeptide Y receptor and method of making the receptor are provided. The invention includes DNA encoding the receptor, the receptor, assays employing the receptor, cells expressing the receptor, antibodies which bind specifically to the receptor, RNA encoded by the DNA sequence or its complementary sequence, and single-stranded DNA with a sequence complementary to the RNA which encodes the receptor. The receptor and assays employing the receptor are useful for identifying compounds which bind to the receptor, including specific modulators of the receptor. Such compounds are useful for treating a variety of disease conditions, including obesity, diabetes, anxiety, hypertension, cocaine withdrawal, congestive heart failure, memory enhancement, cardiac and cerebral vasospasm, pheochromocytoma and ganglioneuroblastoma, and Huntington's, Alzheimer's and Parkinson's diseases.

US Patent:

59088303, Jun 1, 1999

Filed:

Oct 30, 1997

Appl. No.:

8/961749

Inventors:

Roy G. Smith - Westfield NJ
Margaret A. Cascieri - East Windsor NJ
Euan MacIntyre - Scotch Plains NJ
Douglas J. MacNeil - Westfield NJ
John G. Menke - Morganville NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3800
A61K 3124
C07K 500
C07K 1600

US Classification:

514 12

Abstract:

The combination of a metabolic rate modifying agent (e. g. , a. beta. sub. 3 adrenergic receptor agonist) and a feeding behavior modifying agent (e. g. , a NPY5 antagonist) is useful in the treatment of obesity and diabetes, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients. Methods of treating obesity and diabetes are also described.

US Patent:

58891676, Mar 30, 1999

Filed:

May 21, 1997

Appl. No.:

8/859873

Inventors:

Margaret A. Cascieri - East Windsor NJ
Gary A. Chicchi - East Brunswick NJ
Michael P. Graziano - Scotch Plains NJ
Patricia J. Hey - Fanwood NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12N 1510
C12N 510
C07K 14705

US Classification:

536 231

Abstract:

A synthetic human glucagon (hGlu) binding protein designated hGlu. DELTA. 252-259 binding protein is cloned, expressed and used in an in vitro assay to screen for compounds that bind to the synthetic binding protein, including compounds that specifically stimulate or inhibit the binding of glucagon to the synthetic receptor. The invention includes the assay, the synthetic binding protein used in the assay, DNA encoding the synthetic binding protein, cells expressing the synthetic binding protein, and compounds identified through the use of the synthetic binding protein.